The growing preference for cell-based assays in drug discovery, increasing funding for cell-based research, and growth in the number of drug discovery activities are the key factors supporting the growth of the market.
The cell-based assays market is projected to reach USD 22.0 billion by 2025 from USD 14.9 billion in 2020, at a CAGR of 8.1% during the forecast period. However, the growth of the market is likely to be restrained by factors such as the high cost of instruments, restrictions on reagent use, and the lack of infrastructure for cell-based research in emerging economies.
Due to the pandemic, companies have scaled up R&D efforts to develop a vaccine and drugs against the SARS-CoV-2 virus. Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output.
The players operating in the market are altering their long-term and short-term growth strategies by tapping into opportunities prevalent in the research market by developing innovative products to combat the pandemic. The increased demand for research on COVID-19 has created a large scope for cell-based 45 assays in viral infection research, vaccine development, and overall drug discovery for both researchers and laboratories.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269
Cell-based assays are employed to shorten the time and increase the throughput needed for these assays. This has significantly increased the demand for cell-based assays to provide an early indication of the toxicity characteristics of the drug candidates.
Cell-based assays are key components in the drug development process. Cell-based assays have several advantages over in vitro biochemical assays. They offer consistent tissue-specific responses in a biologically relevant microenvironment as opposed to biochemical assays.
It is also not possible to prepare or purify every target for biochemical measurement, which is a major factor limiting the applications of biochemical assays. As a result, pharmaceutical & biotechnology companies as well as CROs are replacing biochemical assays with cell-based assays for their lead identification and optimization processes in drug discovery.
The prominent players operating in the cell-based assays market are Danaher Corporation (US), Thermo Fisher Scientific (US), Merck KGaA (Germany), Becton, Dickinson and Company (US).
Research Developments Analysis
- In 2020, Danaher Corporation (US) launched ImageXpress Micro-confocal High-content Imaging System.
- In 2020, Thermo Fisher Scientific (US) acquired Phitonex, Inc. (US). The acquisition of spectral dye platform manufacturer Phitonex will enable Thermo Fisher to offer greater flow cytometry and imaging multiplexing capabilities in protein and cell analysis research.
- In 2020, Charles River Laboratories entered into a multi-year drug discovery collaboration with Karuna Therapeutics, a US-based CRO, to expand its drug discovery capabilities.
- In 2020, Danaher Corporation completed the acquisition of GE Healthcare’s biopharma business and renamed as Cytiva.
- In 2018, Lonza Group AG (Switzerland) established its Collaborative Innovation Center in the new Life Science Park on the outskirts of Haifa, Israel. This center focuses on the R&D projects of Lonza’s Pharma Biotech & Nutrition segment.
The market growth is largely driven by factors such as growing to fund for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematology analyzers.
On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.
Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.
The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R expenditure, and commercial expansion of various pharmaceutical companies.
For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728 The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization.
In 2019, research institutes accounted for the largest share of the market.
The news media has changed enormously in the course of the last 25 years.
Papers are as yet being printed, however progressively, The News Pocket individuals are going to the web for the most recent news.
Online news locales enjoy an immense upper hand over the printed news media.
They can post articles and inclusion of breaking news promptly after it occurring.
With the appearances of Twitter, Instagram and other driving online media stages, news suppliers can be in the focal point of the activity, as it occurs, revealing occasions live.
This has altogether changed the sort of information we routinely read, and it has changed how and when we read it.
